

# CUMULATIVE INDEX: VOLUME 2

First number represents issue, second number represents pagination

## SUBJECT INDEX

Acetylators, 2,54  
 Acute allergic laryngitis, 1,10  
 Acute asthma, *see* Asthma, acute  
 Acute epiglottitis, 1,9  
 Acute respiratory failure, 3,118  
 Acute upper airway obstruction  
   Heimlich maneuver, 1,2  
   backslap, 1,2  
   Choke Saver, 1,2  
   conscious victim, 1,1-3  
   cricothyroidotomy, 1,2-3  
   loud inspiratory stridor, 1,2  
   nasal trauma, 1,3  
   neurological causes, 1,11  
   signs, 1,1, 1,3  
   surgical management, 1,6-11  
   time of onset, 1,1-2  
   tracheal intubation, 1,4  
   treatment, 1,2, 1,3  
   unconscious victim, 1,3-4  
 Adrenalin, 1,17  
 Adult respiratory distress syndrome (ARDS)  
   antibiotics, 3,151-159  
   corticosteroids, 3,151-159  
   defined, 3,100-102  
   diagnosis criteria, 3,100  
   etiologic factors, 3,102, 3,123  
   fluid therapy, 3,125-126  
   gas exchange after recovery, 3,117-118  
   gas exchange during resolution, 3,117  
   gas exchange response to therapy, 3,118-119  
   historical perspective, 3,99-100  
   injury detection, 3,167-168  
   membrane characteristics, 3,111-112  
   microembolism in, 3,105  
   mortality rate, 3,104  
   pathogenesis, 3,104-108  
   pathology, 3,101  
   pathophysiologic correlation, 3,116-117  
   pharmacology, 3,168  
   pulmonary function following, 3,160-164  
   research, 3,165-172  
   respiratory gas exchange, 3,114-122  
   respiratory monitoring, 3,140-150  
   surfactant abnormalities, 3,101-102  
   terminology, 3,100  
   ventilatory management, 3,128-129  
 Afterload reduction, 1,22  
 Airway edema, 1,34, 1,36  
 Airway resistance, 1,36  
   equations, 3,145  
 Albumin (colloid), 3,125-126  
 Alveolar interstitium, 3,110-111  
   transmural pressure (Ptm), 110  
 Alveolar stability, 3,102  
 Aminophylline, 1,17-18  
 Aminosaliclates (PAS), 4,200  
 Antibiotics, 3,155-157  
   advantages of, 3,155-156  
 Antimycobacterial drugs, 4,196-201  
   generalities, 4,196-197

Apnea, 1,12-15  
   emergency situation, 1,13-14  
   infant, 1,12  
   and propoxyphene, 2,65  
   time course, 1,12  
   treatment, 1,12-13  
 ARDS, *see* Adult respiratory distress syndrome  
 Arterial blood gases, 3,142-143  
   alveolar oxygen equation, 3,142  
   measurements, 1,16-17  
 Arytenoidectomy, 1,11  
 Aspen Lung Conference, 16th, 3,100  
 Aspirated oils, 2,80-81  
 Aspiration pneumonia  
   and antibiotics, 3,156  
   and corticosteroids, 3,153  
 Assisted mechanical ventilation (AMV), 3,129,130-131  
 Asthma, acute, 1,16-19  
   assessment, 1,16-17  
   hospitalization for, 1,18-19  
   management, 1,17-19  
   symptoms, 1,16  
 Asthma, extrinsic, 1,16  
 Bacille Calmette-Guerin (BCG), 2,83-84, 4,179-180  
 Bacteriology, 3,167, 4,205  
 Bergen shunt equation, 3,114  
 Beta agonists, 1,17  
 Beta-blocking drugs, 2,85  
 Bleomycin, 2,48, 2,91-92  
 Body weight, 3,141  
 Bohr equation, 3,116, 3,129, 3,143  
   Enghoff modification, 3,115, 3,143  
 Bronchiectasis and ARDS, and heroin, 2,61  
 Bronchodilation, 1,17  
 Bulsulfan (Myeleran), 2,90-91  
 Cafe coronary, 1,1  
 Capreomycin (CM), 4,198-199  
 Carbofuchsin method, 4,183  
 Carbon monoxide poisoning, 1,30  
 Cardiac output changes and arterial oxygenation, 3,119-120  
 Cardiac tamponade, 1,26-27  
 Cardiovascular monitoring, 1,22  
 Charcoal lighter fluid, 2,83  
 Chemotaxis, 3,165-166  
 Chemotherapeutic drug-induced pulmonary disease, *see* Pulmonary disease, chemotherapeutic drug-induced  
 Chest injuries, categories of, 1,24  
 Chest trauma  
   and antibiotics, 3,156  
   and corticosteroids, 3,153  
 Chest wall, 3,144  
 Chlorambucil (Leukeran), 2,92  
 Colloid therapy, 3,125-126  
 Complement system, 3,165-166  
 Computers, 3,146  
 Congestive atelectasis, 3,99  
 Continuous mechanical ventilation (CMV), 1,41  
 Continuous positive airway pressure (CPAP), 3,100, 3,133

Continuous positive pressure breathing (CPPB), 3,100  
 Controlled mechanical ventilation (CMV), 3,129,130  
 Corticosteroids, 2,78-79, 3,151-155  
   advantages, 3,151-152  
   alveolar cell function, enhancing of, 3,152  
   fibrosis, 3,152  
   inflammation reduction, 3,151  
   intracranial pressure, lowering of, 3,152  
   intravascular coagulation or microembolization, 3,151-152  
   pulmonary blood flow, increasing of, 3,152  
 Covalent binding, 2,46, 2,49  
 Cricothyroid muscle, 1,11  
 Cricothyroidotomy, 1,2-3, 1,7  
 Cromolyn sodium, 2,82  
 Cuff pressure, 1,8  
 Cyclophosphamide (Cytoxan), 2,91  
 Cycloserine (CS), 4,200  
 Dantrolene, 2,85  
 Decreased compliance, 1,34  
 Denver, Colorado. National Jewish Hospital, 4,184, 4,236-237  
 Diacetylmorphine, *see* Heroin  
 Diaphragmatic rupture, 1,28  
 Diphenylhydantoin, 2,51, 2,55, 2,85  
 Drug-induced pulmonary disease, *see* Pulmonary disease, drug-induced  
 Drug-induced systemic lupus erythematosus, *see* Systemic lupus erythematosus  
 Drug resistance  
   categories, 4,185-186  
   detection techniques, 4,186  
   international concern, 4,186-187  
 Edema, *see* Pulmonary edema  
 Elastase, 3,166  
 Elastic resistance, 1,35-36  
   increased, 1,34  
 Electrocardiogram (EKG), 3,142  
 Endotoxin, 3,124-125  
 Eosinophilia, 2,72  
 Epinephrine, 1,17  
 Esophageal obturator airway (EOA), 1,14  
 Esophageal rupture, 1,14  
 Ethambutol (EMB), 4,196-199, 4,229-231  
 Ethionamide (ETA), 4,199-200, 4,229-231  
 Expiratory flow rates, 1,6  
 Expired minute volume, 3,143  
 Extra-alveolar interstitium, 3,111  
 Extracorporeal oxygenation, 3,168-169  
 Extrapleural injury, 1,27  
 Extrapulmonary tuberculosis, 4,206,221  
   acute, 4,206  
   chronic, 4,206  
   miliary, 4,206  
   subacute, 4,206  
 Fat embolism syndrome  
   antibiotics, 3,156  
   corticosteroids, 3,153-154  
 Fibrin(ogen), 3,104  
 Fibrinolysis, 3,105  
 Fibronectin, 3,105

# CUMULATIVE INDEX: VOLUME 2

First number represents issue, second number represents pagination

## SUBJECT INDEX

Acetylators, 2,54  
 Acute allergic laryngitis, 1,10  
 Acute asthma, *see* Asthma, acute  
 Acute epiglottitis, 1,9  
 Acute respiratory failure, 3,118  
 Acute upper airway obstruction  
   Heimlich maneuver, 1,2  
   backslap, 1,2  
   Choke Saver, 1,2  
   conscious victim, 1,1-3  
   cricothyroidotomy, 1,2-3  
   loud inspiratory stridor, 1,2  
   nasal trauma, 1,3  
   neurological causes, 1,11  
   signs, 1,1, 1,3  
   surgical management, 1,6-11  
   time of onset, 1,1-2  
   tracheal intubation, 1,4  
   treatment, 1,2, 1,3  
   unconscious victim, 1,3-4  
 Adrenalin, 1,17  
 Adult respiratory distress syndrome (ARDS)  
   antibiotics, 3,151-159  
   corticosteroids, 3,151-159  
   defined, 3,100-102  
   diagnosis criteria, 3,100  
   etiologic factors, 3,102, 3,123  
   fluid therapy, 3,125-126  
   gas exchange after recovery, 3,117-118  
   gas exchange during resolution, 3,117  
   gas exchange response to therapy, 3,118-119  
   historical perspective, 3,99-100  
   injury detection, 3,167-168  
   membrane characteristics, 3,111-112  
   microembolism in, 3,105  
   mortality rate, 3,104  
   pathogenesis, 3,104-108  
   pathology, 3,101  
   pathophysiologic correlation, 3,116-117  
   pharmacology, 3,168  
   pulmonary function following, 3,160-164  
   research, 3,165-172  
   respiratory gas exchange, 3,114-122  
   respiratory monitoring, 3,140-150  
   surfactant abnormalities, 3,101-102  
   terminology, 3,100  
   ventilatory management, 3,128-129  
 Afterload reduction, 1,22  
 Airway edema, 1,34, 1,36  
 Airway resistance, 1,36  
   equations, 3,145  
 Albumin (colloid), 3,125-126  
 Alveolar interstitium, 3,110-111  
   transmural pressure (Ptm), 110  
 Alveolar stability, 3,102  
 Aminophylline, 1,17-18  
 Aminosaliclates (PAS), 4,200  
 Antibiotics, 3,155-157  
   advantages of, 3,155-156  
 Antimycobacterial drugs, 4,196-201  
   generalities, 4,196-197

Apnea, 1,12-15  
   emergency situation, 1,13-14  
   infant, 1,12  
   and propoxyphene, 2,65  
   time course, 1,12  
   treatment, 1,12-13  
 ARDS, *see* Adult respiratory distress syndrome  
 Arterial blood gases, 3,142-143  
   alveolar oxygen equation, 3,142  
   measurements, 1,16-17  
 Arytenoidectomy, 1,11  
 Aspen Lung Conference, 16th, 3,100  
 Aspirated oils, 2,80-81  
 Aspiration pneumonia  
   and antibiotics, 3,156  
   and corticosteroids, 3,153  
 Assisted mechanical ventilation (AMV), 3,129,130-131  
 Asthma, acute, 1,16-19  
   assessment, 1,16-17  
   hospitalization for, 1,18-19  
   management, 1,17-19  
   symptoms, 1,16  
 Asthma, extrinsic, 1,16  
 Bacille Calmette-Guerin (BCG), 2,83-84, 4,179-180  
 Bacteriology, 3,167, 4,205  
 Bergen shunt equation, 3,114  
 Beta agonists, 1,17  
 Beta-blocking drugs, 2,85  
 Bleomycin, 2,48, 2,91-92  
 Body weight, 3,141  
 Bohr equation, 3,116, 3,129, 3,143  
   Enghoff modification, 3,115, 3,143  
 Bronchiectasis and ARDS, and heroin, 2,61  
 Bronchodilation, 1,17  
 Bulsulfan (Myeleran), 2,90-91  
 Cafe coronary, 1,1  
 Capreomycin (CM), 4,198-199  
 Carbofuchsin method, 4,183  
 Carbon monoxide poisoning, 1,30  
 Cardiac output changes and arterial oxygenation, 3,119-120  
 Cardiac tamponade, 1,26-27  
 Cardiovascular monitoring, 1,22  
 Charcoal lighter fluid, 2,83  
 Chemotaxis, 3,165-166  
 Chemotherapeutic drug-induced pulmonary disease, *see* Pulmonary disease, chemotherapeutic drug-induced  
 Chest injuries, categories of, 1,24  
 Chest trauma  
   and antibiotics, 3,156  
   and corticosteroids, 3,153  
 Chest wall, 3,144  
 Chlorambucil (Leukeran), 2,92  
 Colloid therapy, 3,125-126  
 Complement system, 3,165-166  
 Computers, 3,146  
 Congestive atelectasis, 3,99  
 Continuous mechanical ventilation (CMV), 1,41  
 Continuous positive airway pressure (CPAP), 3,100, 3,133

Continuous positive pressure breathing (CPPB), 3,100  
 Controlled mechanical ventilation (CMV), 3,129,130  
 Corticosteroids, 2,78-79, 3,151-155  
   advantages, 3,151-152  
   alveolar cell function, enhancing of, 3,152  
   fibrosis, 3,152  
   inflammation reduction, 3,151  
   intracranial pressure, lowering of, 3,152  
   intravascular coagulation or microembolization, 3,151-152  
   pulmonary blood flow, increasing of, 3,152  
 Covalent binding, 2,46, 2,49  
 Cricothyroid muscle, 1,11  
 Cricothyroidotomy, 1,2-3, 1,7  
 Cromolyn sodium, 2,82  
 Cuff pressure, 1,8  
 Cyclophosphamide (Cytoxan), 2,91  
 Cycloserine (CS), 4,200  
 Dantrolene, 2,85  
 Decreased compliance, 1,34  
 Denver, Colorado. National Jewish Hospital, 4,184, 4,236-237  
 Diacetylmorphine, *see* Heroin  
 Diaphragmatic rupture, 1,28  
 Diphenylhydantoin, 2,51, 2,55, 2,85  
 Drug-induced pulmonary disease, *see* Pulmonary disease, drug-induced  
 Drug-induced systemic lupus erythematosus, *see* Systemic lupus erythematosus  
 Drug resistance  
   categories, 4,185-186  
   detection techniques, 4,186  
   international concern, 4,186-187  
 Edema, *see* Pulmonary edema  
 Elastase, 3,166  
 Elastic resistance, 1,35-36  
   increased, 1,34  
 Electrocardiogram (EKG), 3,142  
 Endotoxin, 3,124-125  
 Eosinophilia, 2,72  
 Epinephrine, 1,17  
 Esophageal obturator airway (EOA), 1,14  
 Esophageal rupture, 1,14  
 Ethambutol (EMB), 4,196-199, 4,229-231  
 Ethionamide (ETA), 4,199-200, 4,229-231  
 Expiratory flow rates, 1,6  
 Expired minute volume, 3,143  
 Extra-alveolar interstitium, 3,111  
 Extracorporeal oxygenation, 3,168-169  
 Extrapleural injury, 1,27  
 Extrapulmonary tuberculosis, 4,206,221  
   acute, 4,206  
   chronic, 4,206  
   miliary, 4,206  
   subacute, 4,206  
 Fat embolism syndrome  
   antibiotics, 3,156  
   corticosteroids, 3,153-154  
 Fibrin(ogen), 3,104  
 Fibrinolysis, 3,105  
 Fibronectin, 3,105

- Fibrosis, 3,166-167  
 Fick principle, 3,135  
 Flail chest, 1,27  
 Fluid therapy, 1,18, 3,125-126  
   albumin, 3,125-126  
   hypovolemic patient, 3,126  
   isotonic salt solution (ISS), 3,125-126  
   maintenance phase, 3,125  
   resuscitation phase, 3,125  
 Forced expiratory volume, 1,17  
 Foreign body aspiration, 1,1
- Glottic area, 1,8-9  
 Gold therapy, 2,80  
 Granuloma formation, 1,8-9  
 Guillain-Barre syndrome, 1,12, 1,35
- Hageman factor (HF) system, 3,105, 3,166  
 Heimlich maneuver, 1,2  
 Hematocrit, 3,142  
 Hemoglobin, 3,142  
 Hemopericardium, 1,27  
 Hemothorax, 1,25-26  
 Heroin, 2,59-62  
   intoxification, 2,59  
   pulmonary complications, 2,59-61  
   pulmonary function studies, 2,61  
   treatment, 2,61-62  
 High altitude pulmonary edema, 2,60-61  
   antidiuresis, 2,61  
 High pressure pulmonary edema, 2,60  
 Hospitalization of patients  
   asthma, 1,18-19  
   tuberculosis, 4,225-226  
 "Hot potato" voice, 1,10, 1,11  
 Hydralazine, 2,51, 2,56  
 Hydrochlorothiazide, 2,85  
 Hydrostatic gradient, 3,112  
 Hydroxyurea, 2,94  
 Hypercapnic respiratory failure, 1,33-37  
   causes, 1,33-35  
   equations, 1,33, 1,34  
   intubation, 1,37  
   pathophysiologic profile, 1,35  
   patient monitoring, 1,36  
   recognition, 1,33  
   treatment, 1,35-36  
   ventilation, 1,37  
 Hypotension, 1,8  
 Hypoxemia in ARDS, 3,131  
 Hypoxemia, mechanisms of, 3,114-115  
   diffusion impairment, 3,115  
   increased shunt, 3,114-115  
   low ventilation to perfusion, 3,115  
   venous admixture, 3,114  
 Hypoxemic respiratory failure, 1,38-42  
   arterial blood gas analysis, 1,38  
   assessment during support, 1,41  
   differential diagnosis, 1,38-39  
   equations, 1,38, 1,39  
   oxygenation, 1,40-41  
   pathophysiology, 1,38  
   recognition, 1,38  
   treatment, 1,40
- Immune system, role of, 2,49  
 Impaired carbon dioxide elimination, 3,115-116  
 Impedance measurement, 3,144  
 Increased airway resistance, 1,34  
 Infantile respiratory distress syndrome, 3,100
- Inspiratory flow rates, 1,6  
 Inspiratory flow resistance, 1,34  
 Inspiratory force, 3,143  
 Inspiratory stridor, 1,2, 1,6  
 Inspired and expired gas analysis, 3,147-148  
 Inspired oxygen, fraction of, 3,128-129  
 Intermittent mandatory ventilation (IMV), 3,129-131  
 Intermittent positive pressure ventilation (IPPV), 3,130  
 Intralipid, 2,83  
 Intubation  
   hypercapnic respiratory failure, 1,37  
   hypoxemic respiratory failure, 1,41  
 Iodized contrast medium, 2,82-83  
 Isoniazid (INH), 3,178-179, 3,197, 4,229-231  
   and rifampin combination, 4,223-224  
 Isoprenaline (Isoproterenol), 2,81  
 Isotonic salt solution (ISS), 3,125-126
- Kanamycin (KM), 4,198-199  
 Koch, Robert, 4,182  
 Kussmaul's sign, 1,26
- Laboratory services for tuberculosis, 4,182-195  
   background, 4,182  
   chemotherapy adequacy, 4,187  
   diagnosis of disease, 4,182-184  
   direct method, 4,183  
   drug resistance, 4,185-187  
   drug susceptibility tests, 4,186-187  
   drug toxicity, 4,187  
   fluorochrome method, 4,183  
   level concept, 4,188-189  
   laboratory data, 4,191-192  
   mycobacterial pathogens, 4,184-185  
   noncooperative patients, 4,188  
   responsibilities, 4,182-183  
   scope and capabilities, 4,191  
   specimens collection, 4,189-190  
   specimens transport, 4,191  
   studies, 4,186-187  
 Laerdal system, 1,13  
 Laryngeal injury, 1,7-8  
 Laryngeal nerve, recurrent, 1,11  
 Leukoagglutinins, 2,82  
 Lipid peroxidation, 2,48  
 Ludwig's angina, 1,10  
 Lung  
   effects of drugs on, *see* Individual drugs  
   injury, 3,124-125  
   physiology, 3,123-124  
 Lung transplantation, 3,169  
 Lung, two-compartment, 3,109  
 Lymphangiograms, 2,82-83
- Mass spectrometry, 3,146-147  
 Mechanics, bedside measurement, 3,144  
 Metabolic activation, 2,45  
 Methadone, 2,62-63  
   effects on respiration, 2,62-63  
   lung injury, mechanism of, 2,63  
   pulmonary edema, 2,62  
   use and abuse, 2,62  
 Mercury, 2,83  
 Methotrexate, 2,93  
 Methyldopa, 2,55  
 Methysergide, 2,84  
 Metoprolol, 2,85
- Microembolism syndrome, 3,105  
 Microvascular, 3,109  
 Miliary tuberculosis, diagnosis of, 4,207  
 Mitomycin, 2,94  
 Morphine, *see* Heroin  
 Mycobacterium avium-intracellulare complex disease, 4,233-239  
   chemotherapy, 4,235-236  
   diagnostic considerations, 4,233-235  
   disease criteria, 4,234  
   drugs and dosage, 4,237  
   extrapulmonary disease, 4,238  
   National Jewish Hospital, 4,236-237  
   pathogenesis, 4,234-235  
   predisposing factors, 4,233  
   surgery, 4,237-238  
   treatment, 4,235-238  
 Mycobacterium fortuitum complex organisms, 4,240-243  
   case summary, 4,241  
   clinical data, 4,240-241  
   discussion, 4,241-242  
   optimal therapy, 4,242  
   resistance of, 4,240  
 Mycobacterium Kansaii, 4,228-232  
   chemotherapy evaluation, 4,229-230  
   diagnostic criteria, 4,228-229  
   drug toxicity, 4,230  
   recommendations, 4,231  
   relapses, 4,231  
 Myocardial contractility, increased, 1,22
- Nadolol, 2,85  
 Naloxone, 2,61-62, 2,66  
 Narcotism and lung injury  
   incidence, 2,59  
   lung pathology, 2,66  
 Nasal trauma, 1,3  
 Nasogastric tube, 1,28  
 Nasotracheal intubation, 1,14  
 Neoplasms of upper airway, 1,11  
 Neurogenic pulmonary edema, 3,152  
 Neuromuscular disease, 1,35  
 Nitrofurantoin, pulmonary reaction to, 2,70-75  
   acute form, 2,71-72  
   case histories, 2,72, 2,73-74  
   chronic form, 2,72-73  
   clinical features, 2,71  
   diagnosis, 2,74  
   histopathology, 2,71  
   hypoxemia, 2,72  
   incidence, 2,70  
   pathogenesis, 2,70-71  
   therapy and prognosis, 2,74  
 Nitrosoureas, 2,92-93
- On-line mechanics, 3,148-149  
 Oral contraceptives, 2,84-85  
 Orotracheal intubation, 1,13  
 Osmolar clearance, 3,141  
 Osmotic gradient, 3,112  
 Overperfusion pulmonary edema, 3,106  
 Oxygenation, arterial, and cardiac output, 3,119-120  
 Oxygenation, improved, 1,21  
 Oxygen consumption and transport, 3,120-121  
 Oxygen therapy, 1,17, 1,30-32, 1,35  
   controlled respiration, 1,31-32  
   drug-induced pulmonary disease, 2,80  
   hypoxemic respiratory failure, 1,40  
   masks, 1,30-31  
   oxygen flow, 1,31  
   spontaneous respiration, 1,30-31

Oxygen toxicity, 2,46-47, 3,129  
antibiotics, 3,156  
corticosteroids, 3,154  
Oxygen uptake, 3,120

#### Pancreatitis

and antibiotics, 3,156  
and corticosteroids, 3,154  
Paraquat toxicity, 2,47-48  
PEEP, *see* Positive and expiratory pressure  
Penicillamine therapy, 2,53, 2,85  
Wilson's disease, 2,56

Pericardiocentesis, 1,26-27

Perimicrovascular, 3,109

Peritonitis abscess (Quinsy), 1,10

Perivascular osmotic pressure, 3,112

Permeability edema, 1,40, 2,60, 3,110

Physical examination, 3,141

Physiologic dead space, 3,143-144

Pituitary snuff, 2,82

Plasma and urine osmolality, 3,141

Platelets and ARDS, 3,166

Pleural effusion, 2,94

Pleuropulmonary fibrosis, 2,84

Pneumonia and heroin, 2,61

Pneumonitis, nitrofurantoin induced, 2,72

Pneumotachographs, 3,148

Fleish, 3,148

Pneumothorax, 1,24-25

open, 1,24

simple, 1,24

signs of, 1,25

technical considerations in decompressing the pleural space, 1,25-26

tension, 1,24-25

Polymorphonuclear neutrophils, 3,165-166

Polymyxin, 2,82

Positive end expiratory pressure (PEEP),

2,59, 3,128-129

and ARDS, 3,118

barotrauma, 3,133

best PEEP, 3,119, 3,131, 3,134

effect on cardiac output, 3,132-133, 3,135

effect on oxygenation and lung volume, 3,131-132

effect on wedge pressure, 3,136

evaluation and application, 3,134-136

goals, 3,133-134

hypoxemic respiratory failure, 1,41

minimal, 3,133

optimal level, 3,119, 3,134

prophylactic, 3,136

reduction, 3,136-137

super PEEP, 3,133, 3,134

Preload reduction, 1,21-22

Pre-vertebral space abscess, 1,10

Propanolol, 2,85

Propoxyphene, 2,63-66

apnea, 2,65

characteristics, 2,64

lung injury, mechanism of, 2,65

lung pathology, 2,65-66

mortality, 2,65

overdose and abuse, 2,64-65

pulmonary edema, 2,65

structure, 2,63-64

treatment, 2,66

Procainamide, 2,51, 2,55, 2,56

Procarbazine, 2,93-94

Prostheses, implantation of, 3,169

Proteases and acute lung injury, 3,104

Pulmonary disease, chemotherapeutic

drug-induced, 2,89-96

classification, 2,89, 2,90

drugs, 2,90-94

literature review, 2,89-90

mechanism of, 2,89

radiation therapy, 2,94

symptoms, 2,90

Pulmonary disease, drug-induced, 2,76-88

adverse drug reactions, 2,76

anti-inflammatory/immunosuppressive

agents, 2,78-80

classifications, 2,77

inhalants, 2,80-82

intravenous agents, 2,82-83

miscellaneous agents, 2,83-86

Pulmonary disease, drug-induced, molec-

ular mechanisms of, 2,45-50

alkylating drug intermediates, 2,48-49

immune system, role of, 2,49

nitrofurantoin, 2,48

oxygen toxicity, 2,46-47

paraquat toxicity, 2,47-48

Pulmonary edema, 1,20-23

afterload reduction, 1,22

defined, 1,20

etiologic factors, 1,21

improved oxygenation, 1,21

incidence, 1,20-21

increased myocardial contractility, 1,22

leakage sites, 3,109-110

membrane characteristics, 3,111-112

preload reduction, 1,21-22

treatment, 1,21-22

Pulmonary edema and heroin, 2,59-61

antidiuresis, 2,61

high altitude, 2,60-61

high pressure, 2,60

hypoxemia, 2,60

immunologic abnormalities, 2,61

mortality rate, 2,59

permeability, 2,60

Pulmonary edema and methadone, 2,62

Pulmonary edema and propoxyphene, 2,65

Pulmonary function following ARDS,

3,160-164

case histories, 3,161-164

lung recovery, 3,161

mortality rate, 3,160

oxygen toxicity, 3,161

Pulmonary granulomatosis, 2,66-67

Pulmonary infiltrate/eosinophilia (PIE),

2,85-86

Pulmonary microvascular injury, putative

mediators of, 3,106

Pulmonary oxygen toxicity, 1,30

Pulmonary vascular resistance (PVR),

3,132

Pulsus paradoxus, 1,16, 1,26

Pyrazinamide (PZA), 4,198

Radiation pneumonitis, 2,94

and antibiotics, 3,156

and corticosteroids, 3,154

Radiation therapy, 2,94

Radiologic examination, 3,142

Reflection coefficient, 3,112

Respiratory acidosis, 1,35

Respiratory burns and smoke inhalation

and antibiotics, 3,156

and corticosteroids, 3,154-155

Respiratory monitoring, 1,41, 3,140-150

computers, 3,146

diagnostic studies, 3,140-146

inspired and expired gas analysis,

3,147-148

mass spectrometry, 3,146-147

on-line mechanics, 3,148-149

technique development, 3,149

Respiratory tract burns, 1,9

Respiratory muscle weakness, 1,33

Retropharyngeal space abscess, 1,10

Rib fracture, 1,26

Rifampin (RM), 3,197-198, 4,229-231

and isoniazid combination, 4,223-224

Runyon classification, 4,184

Salicylates, 2,79-80

Salpingitis, 4,211

Self-assessment questions, 1,4-5,15,19,29,

32,37,42; 2,50,58,69,75,88,96; 3,103,

108,113,122,127,139,150,158-159,

164,171-172; 4,181,194-195,201,

213-214,226-227,232,239,242-243

answers, 1,43, 2,98, 3,174, 4,245

Sepsis and shock

and antibiotics, 3,156-157

and corticosteroids, 3,155

Shunt, 3,129

Siggard-Anderson Nomogram, 1,37

Sputum, processing of, 4,184

Starling equation, 1,20, 1,39, 1,40, 3,123

lung fluid increase, 1,20

Static compliance, 3,145

curve, 3,148

total, 3,130, 3,135

Staub equation, 3,109

Stiff lungs, 3,99, 3,102

Streptomycin (SM), 4,198-199

Stricture formation, 1,8

Surfactant, 3,167

Surfactant abnormalities, in ARDS,

3,101-102

Systemic lupus erythematosus (SLE),

2,51-58

antinuclear antibody specificity, 2,53

clinical manifestations, 2,51-52

diagnosis, 2,51

drug metabolism, 2,53-54

drugs that may induce, 2,51

hypersensitivity reaction, 2,54

immune response, inhibition of, 2,54

laboratory abnormalities, 2,52-53

nuclear constituents, 2,54

pathogenesis, 2,53-55

potential SLE-inducing drugs, 2,56

treatment, 2,55-56

Thoracic aortic injury, 1,27-28

Thyroidectomy, 1,11

Tidal volume, 3,130,143

Timolol, 2,85

Tracheal injury, 1,7-8

Tracheal intubation, 1,4

Tracheal stenosis, 1,8

Tracheobronchial rupture, 1,28

Tracheostomy, 1,6-7

Traumatic wet lung, 3,99

Truant technique, 4,183

Tuberculin test, 4,203-205

anergy skin tests, 4,204

booster effect, 4,204-205

false-negative result, 4,204

Mantoux test, 4,203-204

multiple puncture tests, 4,203

patch test, 4,203

tuberculin, 4,203

Tuberculosis

antimycobacterial drugs, 4,196-201

changes in care for, 4,176  
 contacts of patients, 4,176-177  
 containment of, 4,176  
 diagnosis, 4,202-214; *See also* Tuberculosis, diagnosis  
 incidence, 4,175  
 infectiousness of patients, 4,175-176  
 laboratory, role of, 4,182-195; *See also* Laboratory services  
 preventive therapy, 4,177-179  
 suspecting, 4,175  
 treatment, 4,215-227; *See also* Tuberculosis, treatment  
 vaccination, 4,179-180  
 Tuberculosis, diagnosis, 4,202-214  
 bacteriology, 4,205  
 bone and joint, 4,209-210  
 chest x-ray, 4,206  
 exposure history, 4,203  
 extrapulmonary, 4,206  
 genitourinary, 4,210-211  
 lymph node, 4,212-213  
 medical history, 4,203  
 meningeal, 4,207-208  
 miliary, 4,207  
 pericardial, 4,208-209  
 peritoneal, 4,209  
 physical examination, 4,202-203  
 pleura, 4,210  
 skin, 4,212  
 thoracic symptoms, 4,202  
 tuberculin test, 4,203-205; *See also* Tuberculin test  
 upper respiratory tract, 4,211-212  
 Tuberculosis, treatment, 4,215-227  
 chemotherapy, 4,216,224  
 children, 4,221-222  
 continuation phase of original treatment, 4,218-219  
 drug-resistant, 4,219-221  
 drugs, choice of, 4,215-216  
 extrapulmonary, 4,221  
 hepatitis, 4,222  
 hospitalization for, 4,225-226

initial phase of original treatment, 4,216-218  
 pregnancy, 4,222  
 pretreatment drug susceptibility studies, 4,222-223  
 private physician, 4,224-225  
 renal failure, 4,222  
 self-administered versus supervised treatment, 4,224  
 toxicity, 4,223-224

U.S. National Academy of Sciences-National Research Council. Committee on Trauma of the Division of Medical Sciences. 1968 Conference, Washington D.C., 3,99-100

Upper airway obstruction, *see* Acute upper airway obstruction

Urine output, 3,141

Urine specific gravity, 3,141

Urokinase Streptokinase Pulmonary Embolism Trial (UPSET) study, 2,84-85

Valsalva maneuver, 1,26

Venous admixture equation, 3,114

Venous return (VR), 3,132

Ventilation

hypoxemic respiratory failure, 1,41

mechanical, 1,18, 3,129-131

tidal volume mode, 3,128-131

Ventilators, 3,169

Vocal cord paralysis, 1,11

World Health Organization (WHO), on laboratory services, 4,183,186,192

Xanthine derivatives, 1,17-18

Ziehl-Neelsen technique, 4,183

## AUTHORS' INDEX

Ahn, Chai H., 4,228-232

Albert, Richard K., 3,109-113

Ali, Jameel, 1,24-29

Bone, Roger C., 3,140-150

Brashear, Richard E., 2,59-69

Bristow, Gerald, 1,1-5, 1,12-15, 1,16-19, 1,20-23, 1,30-32

Carrico, C. James, 3,123-127

Dalovisio, Joseph R., 4,240-243

Davidson, Paul T., 4,215-232, 4,233-239

Farer, Laurence S., 4,175-181

Fernandez, Enrique, 4,202-214

Gangadharam, Pattisapu R., 4,182-195

Ginsburg, William W., 2,51-58

Goble, Marian, 4,215-232

Hempel, Franklin G., 3,165-172

Hudson, Leonard D., 3,128-139, 3,160-164

Hurst, George A., 4,228-232

Hyers, Thomas Morgan, 3,104-108

Kirk, Bryan, 1,33-37, 1,38-42

Lakshminarayan, S., 3,160-164

Lauterburg, Bernhard H., 2,45-50

Lefkowitz, Martin S., 4,196-201

Lenfant, Claude J. M., 3,165-172

Luce, John M., 3,150-159

McCullough, David, 1,6-11

Mitchell, Jerry R., 2,45-50

Moulding, Thomas S., 4,215-227

Petty, Thomas L., 3,99-103

Pierson, David J., 3,150-159

Prakash, Udaya B. S., 2,70-75

Rabson, John, 1,20-23

Ralph, David, 3,114-122

Robertson, H. Thomas, 3,114-122

Rosenow, Edward C. III, 2,76-88, 2,89-96

Smith, Charles V., 2,45-50

Stohtert, Joseph C. Jr., 3,123-127